Collaborative Clinical Trials in Drug Abuse (R01)

The summary for the Collaborative Clinical Trials in Drug Abuse (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Collaborative Clinical Trials in Drug Abuse (R01)
	CFDA Number:	93.279
	CFDA Description:	Drug Abuse and Addiction Research Programs
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PAR-07-232
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Feb 23, 2007
	Creation Date:	Dec 05, 2008
	Original Closing Date for Applications:	Multiple Receipt Dates - See Link to Full Announcement for details.
	Current Closing Date for Applications:	Multiple Receipt Dates - See Link to Full Announcement for details.
	Archive Date:	Feb 02, 2010
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Grant Description: -This Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse, National Institutes of Health, is a reissuance of PAR-04-073, Collaborative Clinical Trials in Drug Abuse, published in the NIH Guide for Contracts and Grants, March 9, 2004 at http://grants.nih.gov/grants/guide/pa-files/PAR-04-073.html. This announcement provides guidelines for the development, review, and funding of Collaborative Clinical Trials in Drug Abuse (CCTDA) through the solicitation of Research Project Grant (R01) applications from institutions/organizations that propose to carry out clinical trials using a common protocol at collaborating sites. One of the sites should be the coordinating site for the trial. Each site must submit a separate R01 application. Although a foreign institution may be a participating site, the coordinating site must be a domestic institution. -Purpose. The National Institute on Drug Abuse (NIDA) seeks to increase the collaboration of investigators at different sites in order to address critical issues in the treatment of substance-related disorders that require sample sizes greater than a single site can reasonably attain. The expectation for the collaborative effort is that there will be implementation of common clinical trials across different sites in order to study patient outcomes, patient factors, provider factors, setting characteristics, interactions of these, or other effects where pooled samples are appropriate and necessary for the hypotheses under consideration. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/par-07-232.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1); • Pre-Application for the FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (X02); • Pre-Application for the 2012 NIDA Translational Avant-Garde Award for Medication Development for the...; • 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance ...; • International Tobacco and Health Research and Capacity Building Program (R01); • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • DRUG ABUSE ASPECTS OF HIV/AIDS AND OTHER INFECTIONS; • EPIDEMIOLOGY OF DRUG ABUSE; • PRESCRIPTION DRUG ABUSE; • MDMA: RESEARCH AREAS NEEDING MORE EMPHASIS